Article
Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients.
Clinical pharmacokinetics - 1 Jul 2011
Glowacki François, Lionet Arnaud, Hammelin Jean-Philippe, Labalette Myriam, Provôt François, Hazzan Marc, Broly Franck, Noël Christian, Cauffiez Christelle
Abstract excerpt
BACKGROUND AND OBJECTIVE: Tacrolimus is metabolized by cytochrome P450 (CYP) 3A5. The objective of this study was to investigate the influence of the genetic polymorphism of CYP3A5 on the pharmacokinetics of a new modified-release, once-daily formulation of tacrolimus (Advagraf®) after a switch from the immediate-release formulation (Prograf®). PATIENTS AND METHODS: This was a prospective, single-centre,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.